IPR-179 (ACT-03) is a potent, BBB-permeable, selective gelatinase (MMP2 and MMP9) inhibitor with IC50 of 656 nM and 310 nM, respectively.
IPR-179 dispalys high selectivity over MMP1/3/7/8, ADAM10/17, Prolyl oligopeptidase and DPP4 (IC50=3.3 uM->20 uM).
IPR-179 reduced seizure severity in the rapid-kindling rat model.
IPR-179 reduced the number of spontaneous seizures in the kainic acid model (during and up to 7 weeks after delivery) without side effects while improving cognitive behavior.
IPR-179 prevented an MMP2/9-dependent switch-off normally restraining network excitability during the activity period.
